Study for children with myotonic dystrophy
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study looks at how to best measure muscle health and function in children with myotonic dystrophy. It may help prepare for future treatment trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 17 years old (with some exceptions for those in earlier studies).
- You must have a diagnosis of congenital or childhood myotonic dystrophy confirmed by genetic testing.
- You cannot have other illnesses that would make testing unsafe or affect results.
- You cannot take blood thinners like warfarin or dabigatran, or have a bleeding disorder.
- You cannot have metal inside your body (for a bone density scan).
- You cannot be in another investigational drug trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how safe and effective tideglusib is for children and young adults with congenital or childhood-onset myotonic dystrophy type 1 (DM1). It may help researchers learn whether the medicine improves symptoms while tracking side effects closely.
This study looks at measurements and child-focused outcomes in babies and toddlers with myotonic dystrophy type 1 (DM1) that started in the newborn period. It may help researchers better track how the condition affects children and evaluate care plans more accurately.
This study is a long-term follow-up for people with myotonic dystrophy type 1. It aims to find better ways to measure how the disease progresses, which could help develop future treatments.
This study uses MRI scans to measure muscle changes in people with myotonic dystrophy (DM1 or DM2) and healthy volunteers. The goal is to find better ways to track the disease over time.
This study collects blood and, for some people, muscle tissue to look for signs (biomarkers) that can help track and better understand myotonic dystrophy. You may help by providing samples and basic muscle function testing, depending on your age and condition type.
This study builds a registry of people and families affected by myotonic dystrophy types 1 and 2. It helps researchers learn about the condition over time and may support future studies that could lead to better care.
Hear when a new Congenital Myotonic Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.